UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________

FORM 10-Q/A

______________________________________________________

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31, 2014~~September 30, 2013



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________



Commission File Number: 0-24249

PDI, Inc.
(Exact name of registrant as specified in its charter)

Delaware		22-2919486
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification No.)

Morris Corporate Center 1, Building A
300 Interpace Parkway, Parsippany, NJ 07054
(Address of principal executive offices and zip code)

(800) 242-7494
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer o	Accelerated filer o	Non-accelerated filer o	Smaller reporting company x
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:



Class	Shares Outstanding ~~May 2, 2014~~November 10, 2013
Common stock, $0.01 par value	~~15,322,318~~15,155,242

Explanatory Note

This Amendment No. 1 on Form 10-Q/A (this Amendment) amends the Company's Quarterly Report on Form 10-Q for the quarter ended ~~March 31, 2014~~September 30, 2013 (the Original Filing), as originally filed on ~~May 8, 2014, solely~~November 13, 2013, to amend Exhibit 10.1 to reflect the confidential treatment of specific portions of the Collaboration Agreement dated as of August 19, 2013 and to expand the description of the counterparty in the collaboration agreement with the privately held, emerging molecular diagnostics company (the Diagnostics Company) in Note 13 to the consolidated financial statements and Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. For the convenience of the reader, this Amendment restates in its entirety the Original Filing.

PDI, Inc.

Form ~~10-Q~~10-Q/A for Period Ended ~~March 31, 2014~~September 30, 2013

TABLE OF CONTENTS



		Page No.
	PART I - FINANCIAL INFORMATION

Item 1.	Unaudited Interim Condensed Consolidated Financial Statements

	Condensed Consolidated Balance Sheets at ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012 (unaudited)	43

	Condensed Consolidated Statements of Operations and Comprehensive ~~Income (Loss)~~Loss for the ~~three-month~~three- and nine-month periods ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012 (unaudited)	54

	Condensed Consolidated Statements of Cash Flows for the ~~three-month~~nine-month periods ended ~~March 31, 201~~4September 30, 2013 and ~~2013~~2012 (unaudited)	65

	Notes to Unaudited Interim Condensed Consolidated Financial Statements	76

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2630

Item 4.	Controls and Procedures	2630


	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	2731

Item 1A.	Risk Factors	2731

Item 5.	Other Information	2732

Item 6.	Exhibits	2832

Signatures		2934

PDI, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share and per share data)


	March 31, 2014			December 31, 2013			September 30, 2013			December 31, 2012
ASSETS
Current assets:
Cash and cash equivalents	$	37,878		$	45,639		$	49,627		$	52,783
Short-term investments	103			103			96			92
Accounts receivable, net	8,471			2,422			4,020			10,687
Unbilled costs and accrued profits on contracts in progress	5,558			7,982			6,645			1,955
Other current assets	6,999			6,563			6,136			6,066
Total current assets	59,009			62,709			66,524			71,583
Property and equipment, net	2,846			2,789			3,122			2,396
Goodwill	2,523			2,523			2,523			2,523
Other long-term assets	1,004			1,043			1,045			1,945
Total assets	$	65,382		$	69,064		$	73,214		$	78,447

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	2,493		$	2,350		$	1,768		$	3,388
Unearned contract revenue	8,785			9,379			12,018			14,501
Accrued salary and bonus	7,163			9,643			7,631			6,674
Other accrued expenses	10,863			10,028			10,209			11,827
Total current liabilities	29,304			31,400			31,626			36,390
Long-term liabilities	4,736			5,185			5,581			6,427
Total liabilities	34,040			36,585			37,207			42,817

Commitments and contingencies (Note 7)

Stockholders’ equity:
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding	—			—			—			—
Common stock, $.01 par value; 40,000,000 shares authorized
16,512,332 and 16,316,169 shares issued, respectively;
15,322,318 and 15,169,898 shares outstanding, respectively	165			163
16,281,305 and 16,063,514 shares issued, respectively;
15,149,357 and 14,965,875 shares outstanding, respectively							163			161
Additional paid-in capital	130,917			130,229			130,025			128,508
Accumulated deficit	(85,435		)	(83,823		)	(80,157		)	(79,258		)
Accumulated other comprehensive income	16			16			13			11
Treasury stock, at cost (1,190,014 and 1,146,271 shares, respectively)	(14,321		)	(14,106		)
Treasury stock, at cost (1,131,948 and 1,097,639 shares, respectively)							(14,037		)	(13,792		)
Total stockholders' equity	31,342			32,479			36,007			35,630
Total liabilities and stockholders' equity	$	65,382		$	69,064		$	73,214		$	78,447

The accompanying notes are an integral part of these condensed consolidated financial statements.

PDI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except for per share data)



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2013			2012			2013			2012

Revenue, net	$	34,260		$	31,781		$	114,428		$	91,267
Cost of services	29,564			25,842			94,410			71,392
Gross profit	4,696			5,939			20,018			19,875

Compensation expense	4,231			4,075			13,300			12,726
Other selling, general and administrative expenses	2,517			2,620			7,364			8,442
Total operating expenses	6,748			6,695			20,664			21,168
Operating loss	(2,052		)	(756		)	(646		)	(1,293		)
Other income (expense), net	3			—			(30		)	(15		)
Loss from continuing operations before income tax	(2,049		)	(756		)	(676		)	(1,308		)
Provision for income tax	64			74			192			219
Loss from continuing operations	(2,113		)	(830		)	(868		)	(1,527		)
Loss from discontinued operations, net of tax	(28		)	(189		)	(31		)	(204		)
Net loss	$	(2,141	)	$	(1,019	)	$	(899	)	$	(1,731	)

Other comprehensive income (loss)
Unrealized holding gain (loss) on available-for-sale securities, net	2			(1		)	2			(2		)

Comprehensive loss	$	(2,139	)	$	(1,020	)	$	(897	)	$	(1,733	)

Basic and diluted loss per share of common stock from:
Continuing operations	(0.14		)	$	(0.06	)	(0.06		)	$	(0.10	)
Discontinued operations	(0.01		)	(0.01		)	—			(0.02		)
Net loss per basic and diluted share of common stock	(0.15		)	$	(0.07	)	(0.06		)	$	(0.12	)

Weighted average number of common shares and common share equivalents outstanding:
Basic	14,740			14,609			14,708			14,580
Diluted	14,740			14,609			14,708			14,580

The accompanying notes are an integral part of these condensed consolidated financial statements.

PDI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF ~~COMPREHENSIVE INCOME (LOSS)~~CASH FLOWS

(unaudited, in ~~thousands, except for per share data)~~thousands)

Three Months Ended
March 31,
2014 2013

Revenue, net $ 32,778
$ 42,923
Cost of services 27,669
34,450
Gross profit 5,109
8,473

Compensation expense 3,541
4,155
Other selling, general and administrative expenses 3,065
2,065
Total operating expenses 6,606
6,220
Operating (loss) income (1,497 ) 2,253
Other expense, net (17 ) (9 )
(Loss) income from continuing operations before income tax (1,514 ) 2,244
Provision for income tax 66
64
(Loss) income from continuing operations (1,580 ) 2,180
Loss from discontinued operations, net of tax (32 ) (54 )
Net (loss) income $ (1,612 ) $ 2,126

Other comprehensive income (loss):
Unrealized holding gain (loss) on available-for-sale securities, net —
—
Comprehensive income (loss) $ (1,612 ) $ 2,126

Basic (loss) income per share of common stock from:

Continuing operations $ (0.11 ) $ 0.15
Discontinued operations —
(0.01 )
Net (loss) income per basic share of common stock $ (0.11 ) $ 0.14

Diluted (loss) income per share of common stock from:

Continuing operations $ (0.11 ) $ 0.14
Discontinued operations —
—
Net (loss) income per diluted share of common stock $ (0.11 ) $ 0.14

Weighted average number of common shares and common share equivalents outstanding:

Basic 14,760
14,983
Diluted 14,760
15,074



	Nine Months Ended
	September 30,
	2013			2012
Cash Flows From Operating Activities
Net loss	$	(899	)	$	(1,731	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	922			1,490
Realignment accrual accretion	106			106
Provision for bad debt	9			—
Stock-based compensation	1,519			1,520
Other changes in assets and liabilities:
Decrease in accounts receivable	6,658			1,368
(Increase) decrease in unbilled costs	(4,690		)	1,608
Decrease (increase) in other current assets	2,330			(477		)
Increase in other long-term assets	—			(6		)
Decrease in accounts payable	(1,620		)	(985		)
(Decrease) increase in unearned contract revenue	(2,483		)	368
Increase (decrease) in accrued salaries and bonus	957			(1,263		)
Decrease in other accrued expenses	(1,620		)	(3,813		)
Decrease in long-term liabilities	(952		)	(1,340		)
Net cash provided by (used in) operating activities	237			(3,155		)

Cash Flows From Investing Activities
Purchase of property and equipment	(1,648		)	(528		)
Investment in non-controlled entity	(1,500		)	—
Net cash used in investing activities	(3,148		)	(528		)

Cash Flows From Financing Activities
Cash paid for repurchase of restricted shares	(245		)	(125		)
Net cash used in financing activities	(245		)	(125		)

Net decrease in cash and cash equivalents	(3,156		)	(3,808		)
Cash and cash equivalents – beginning	52,783			64,337
Cash and cash equivalents – ending	$	49,627		$	60,529

The accompanying notes are an integral part of these condensed consolidated financial statements.

~~PDI, INC.~~

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(unaudited, in thousands)~~

Three Months Ended
March 31,
2014 2013
Cash Flows From Operating Activities
Net (loss) income $ (1,612 ) $ 2,126
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

Depreciation and amortization 457
288
Realignment accrual accretion 35
35
Stock-based compensation 690
351
Other changes in assets and liabilities:

(Increase) decrease in accounts receivable (6,049 ) 1,140
Decrease (increase) in unbilled costs 2,424
(5,113 )
Decrease in other current assets 32
330
Decrease in other long-term assets 140
—
Increase in accounts payable 143
690
Decrease in unearned contract revenue (594 ) (626 )
(Decrease) increase in accrued salaries and bonus (2,480 ) 1,143
Increase in other accrued expenses 835
1,128
Decrease in long-term liabilities (484 ) (270 )
Net cash (used in) provided by operating activities (6,463 ) 1,222

Cash Flows From Investing Activities

Purchase of property and equipment (514 ) (445 )
Loan to Diagnostics Company (569 ) —
Net cash used in investing activities (1,083 ) (445 )

Cash Flows From Financing Activities

Cash paid for repurchase of restricted shares (215 ) (227 )
Net cash used in financing activities (215 ) (227 )

Net (decrease) increase in cash and cash equivalents (7,761 ) 550
Cash and cash equivalents – beginning 45,639
52,783
Cash and cash equivalents – ending $ 37,878
$ 53,333

~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular information in thousands, except per share amounts)


1.	BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of PDI, Inc. and its subsidiaries (the Company or PDI) and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2013~~2012 as filed with the Securities and Exchange Commission (SEC) on March ~~6, 2014.~~14, 2013. The interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three and nine-month periods ended ~~three-month period endedMarch 31, 2014~~September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2014~~2013.


2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Estimates

The preparation of ~~consolidated~~the interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenses during the reporting period. Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include incentives earned or penalties incurred on contracts, best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.

Basic and Diluted Net Loss per Share

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted ~~(loss) income~~loss per share for the ~~three-month~~three- and nine-month periods ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012 is as follows:


	Three Months Ended		Three Months Ended		Nine Months Ended
	March 31,		September 30,		September 30,
	2014	2013	2013	2012	2013	2012
Basic weighted average number of common shares	14,760	14,983	14,740	14,609	14,708	14,580
Dilutive effect of stock-based awards	—	91	—	—	—	—
Diluted weighted average number of common shares	14,760	15,074	14,740	14,609	14,708	14,580

The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)


	Three Months Ended		Three Months Ended		Nine Months Ended
	March 31,		September 30,		September 30,
	2014	2013	2013	2012	2013	2012
Options	43	50	42	76	42	76
Stock-settled stock appreciation rights (SARs)	1,238	314	796	574	796	574
Restricted stock/units	754	91	600	632	600	632
Market contingent SARs	188	280
Performance contingent SARs			280	280	280	280
	2,223	735	1,718	1,562	1,718	1,562

Goodwill and Other Intangible Assets

The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the goodwill.

The Company tests goodwill and indefinite lived intangible assets for impairment at least annually (as of December 31) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in expected future cash flows; a sustained, significant decline in stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the pharmaceutical industry; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of goodwill and our consolidated financial results. At ~~March 31, 2014~~September 30, 2013, no indicators of impairment were identified.

Cost of Services - Initial Direct Program Costs

Initial direct program costs are the costs associated with initiating a product detailing program, such as recruiting and hiring and certain other direct incremental costs, excluding pass through costs that are billed to customers. Through March 31, 2012, the Company expensed these initial direct program costs as incurred, as these amounts were not material to the operating results of the Company. As a result of the Company's recent contract signings and plans to enter into larger contracts in the future, requiring more material initial direct program costs, commencing April 1, 2012, the Company changed its policy for the recognition of such initial direct program costs. These costs are now being deferred and amortized to expense in proportion to the revenue recognized as driven by the terms of the contract. This change in accounting was not applied retrospectively because the effect on prior periods was immaterial.

At September 30, 2013 and December 31, 2012, the Company deferred $2.3 million and $1.8 million of initial direct program costs, respectively. For the three month and nine month periods ended September 30, 2013, the Company amortized $0.2 million and $0.7 million of initial direct program costs into expense, respectively. For the three and nine month periods ended September 30, 2012, the Company amortized $0.1 million of initial direct program costs into expense.

Accounting Standards Updates

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, Comprehensive Income (Topic 220), "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," effective for annual and interim reporting periods beginning after December 15, 2012. The new accounting rules require all U.S. public companies to report the effect of items reclassified out of accumulated other comprehensive income on the respective line items of net income, net of tax, either on the face of the financial statements

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

where net income is presented or in a tabular format in the notes to the financial statements. Effective January 1, 2013, the Company adopted ASU No. 2013-02. The new accounting rules expand the disclosure of other comprehensive income and had no impact on the Company's results of operations and financial condition.


3.	INVESTMENTS IN MARKETABLE SECURITIES

Available-for-sale securities are carried at fair value with the unrealized holding gains or losses, net of tax, included as a component of accumulated other comprehensive income ~~(loss)~~ in stockholders’ equity. Realized gains and losses on available-for-sale securities are computed based upon specific identification and included in other income (expense), net in the consolidated statement of operations. Declines in value judged to be other-than-temporary on available-for-sale securities are recorded in other income (expense), net in the consolidated statement of operations and the cost basis of the security is reduced. The fair values for marketable equity securities are based on quoted market prices. Held-to-maturity investments are stated at amortized cost which approximates fair value. Interest income is accrued as earned. Realized gains and losses on held-to-maturity investments are computed based upon specific identification and included in other income (expense), net in the condensed consolidated statement of ~~comprehensive (loss) income.~~operations. The Company does not have any investments classified as trading.

Available-for-sale securities consist of assets in a rabbi trust associated with the Company’s deferred compensation plan. As of ~~both~~ ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, the carrying value of available-for-sale securities was approximately $~~103,000~~96,000 and $92,000, respectively, and is included in short-term investments. Available-for-sale securities ~~as of both~~at ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012 consisted of ~~approximately~~ $~~55,000~~48,000 and $44,000, respectively, in mutual funds, and approximately $48,000 and $48,000, respectively, in money market accounts.

~~PDI, Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)~~

~~(Tabular information in thousands, except per share amounts)~~

The Company’s other marketable securities consist of investment grade debt instruments such as obligations of U.S. Treasury and U.S. Federal Government agencies. These investments are categorized as held-to-maturity since the Company’s management has the ability and intent to hold these securities to maturity. The Company’s held-to-maturity investments are carried at amortized cost which approximates fair value and are maintained in separate accounts to support the Company’s letters of credit. The Company had standby letters of credit of approximately $2.0 million as of ~~both~~ ~~March 31, 2014~~September 30, 2013 and $2.6 million at December 31, ~~2013~~2012, as collateral for its existing insurance policies and facility leases.

At ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, held-to-maturity investments included the following:


			Maturing						Maturing						Maturing						Maturing
	March 31, 2014		within 1 year		after 1 year through 3 years		December 31, 2013		within 1 year		after 1 year through 3 years		September 30, 2013		within 1 year		after 1 year through 3 years		December 31, 2012		within 1 year		after 1 year through 3 years
Cash/money accounts	$	135	$	135	$	—	$	116	$	116	$	—	$	44	$	44	$	—	$	76	$	76	$	—
US Treasury securities	1,477		636		841		1,730		1,360		370		1,370		1,370		—		2,450		1,051		1,399
Government agency securities	623		476		147		382		382		—		822		822		—		1,270		881		389
Total	$	2,235	$	1,247	$	988	$	2,228	$	1,858	$	370	$	2,236	$	2,236	$	—	$	3,796	$	2,008	$	1,788

At ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, held-to-maturity investments were recorded in the following accounts:


	March 31, 2014		December 31, 2013		September 30, 2013		December 31, 2012
Other current assets	$	1,247	$	1,858	$	1,349	$	2,008
Other long-term assets	988		370		887		1,788
Total	$	2,235	$	2,228	$	2,236	$	3,796


4.	GOODWILL AND OTHER INTANGIBLE ASSETS

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

Goodwill recorded as of ~~March 31, 2014~~September 30, 2013 is attributable to the 2010 acquisition of Group DCA. As of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, the carrying amount of goodwill for Group DCA was $2.5 million.

No amortization expense was recorded in 2013 as the Company's finite lived intangible assets were written-off in the fourth quarter of 2012. Amortization expense was $0.2 million ~~million.~~for the three-month period endedSeptember 30, 2012 and $0.7 million for the nine-month period endedSeptember 30, 2012.


5.	FACILITIES REALIGNMENT

The following table presents a rollforward of the Company’s restructuring reserve from December 31, ~~2013~~2012 to ~~March 31, 2014~~September 30, 2013, of which approximately $~~1.1~~1.0 million ~~million~~ is included in other accrued expenses and $~~0.6~~1.2 million ~~million~~ is included in long-term liabilities as of ~~March 31, 2014~~September 30, 2013. The Company recognizes accretion expense in Other ~~expense,~~income (expense), net in the Condensed Consolidated Statement of Operations and Comprehensive ~~(Loss) Income.~~Loss.


	Sales Services			Marketing Services			Discontinued Operations			Total			Sales Services			Marketing Services			Discontinued Operations			Total
Balance as of December 31, 2013	$	1,125		$	458		$	379		$	1,962
Balance as of December 31, 2012													$	2,027		$	637		$	615		$	3,279
Accretion	27			—			8			35			84			—			22			106
Adjustments	—			(16		)	—			(16		)	—			—			—			—
Payments	(168		)	(36		)	(53		)	(257		)	(841		)	(157		)	(211		)	(1,209		)
Balance as of March 31, 2014	$	984		$	406		$	334		$	1,724
Balance as of September 30, 2013													$	1,270		$	480		$	426		$	2,176


6.	FAIR VALUE MEASUREMENTS

The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent

~~PDI, Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)~~

~~(Tabular information in thousands, except per share amounts)~~

consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:


Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.


Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.


Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the ~~tables~~table below.

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)


	As of March 31, 2014				Fair Value Measurements						As of September 30, 2013				Fair Value Measurements
	Carrying		Fair		As of March 31, 2014						Carrying		Fair		As of September 30, 2013
	Amount		Value		Level 1		Level 2		Level 3		Amount		Value		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents:
Cash	$	8,557	$	8,557	$	8,557	$	—	$	—	$	12,303	$	12,303	$	12,303	$	—	$	—
Money Market Funds	29,321		29,321		29,321		—		—
Money market funds											37,324		37,324		37,324		—		—
Total	$	37,878	$	37,878	$	37,878	$	—	$	—	$	49,627	$	49,627	$	49,627	$	—	$	—

Marketable securities:
Money Market Funds	$	48	$	48	$	48	$	—	$	—
Mutual Funds	55		55		55		—		—
Money market funds											$	48	$	48	$	48	$	—	$	—
Mutual funds											48		48		48		—		—
U.S. Treasury securities	1,477		1,477		1,477		—		—		1,370		1,370		1,370		—		—
Government agency securities	623		623		623		—		—		822		822		822		—		—
Total	$	2,203	$	2,203	$	2,203	$	—	$	—	$	2,288	$	2,288	$	2,288	$	—	$	—

The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of ~~March 31, 2014~~September 30, 2013, the Company did not have any marketable securities in less active markets (level 2) or ~~without observable market values that would require a high level of judgment to determine fair value~~ (level 3).

The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.


7.	COMMITMENTS AND CONTINGENCIES

~~PDI, Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)~~

~~(Tabular information in thousands, except per share amounts)~~

Letters of Credit

As of ~~March 31, 2014~~September 30, 2013, the Company had outstanding letters of credit of $2.0 million as required by its existing insurance policies and facility leases. These letters of credit are supported by investments in held-to-maturity securities. See Note 3, Investments in Marketable Securities, for additional detail regarding investments in marketable securities.

Litigation

Due to the nature of the businesses in which the Company is engaged, such as product detailing and in the past, the distribution of products, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or distributes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products, including pharmaceuticals. The Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

The Company routinely assesses all of its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. ~~As of March 31, 2014, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.~~


8.	ACCRUED EXPENSES AND LONG-TERM ~~LIABILITIES~~LIABILTIES

Other accrued expenses consisted of the following as of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012:


	March 31, 2014		December 31, 2013		September 30, 2013		December 31, 2012
Accrued pass-through costs	$	2,397	$	2,089	$	1,772	$	3,729
Accrued reorganization expense	1,124		997		1,005		1,495
Self insurance accruals	496		1,020		841		900
Indemnification liability	875		875		875		875
All others	5,971		5,047		5,716		4,828
	$	10,863	$	10,028	$	10,209	$	11,827

Long-term liabilities consisted of the following as of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012:

~~PDI, Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)~~

~~(Tabular information in thousands, except per share amounts)~~


	March 31, 2014		December 31, 2013		September 30, 2013		December 31, 2012
Rent payable	$	846	$	969	$	1,187	$	1,533
Uncertain tax positions	3,148		3,109		3,082		2,967
Restructuring	600		965		1,171		1,785
Other	142		142		141		142
	$	4,736	$	5,185	$	5,581	$	6,427


9.	STOCK-BASED COMPENSATION

~~In February 2014,~~On April 4, 2013, under the terms of the stockholder-approved PDI, Inc. 2004 Stock Award Incentive Plan (the 2004 Plan), the Compensation and Management Development Committee of the Board (the Compensation Committee) approved grants of restricted stock to certain executive officers and members of senior management of the Company. The full Board approved the portion of these grants made to the Company’s Chief Executive Officer. As part of the Company's ~~2013~~2012 long-term incentive plan, these grants aggregated ~~173,990~~143,695 shares of restricted stock issued with a ~~weighted average~~ grant date fair value of $~~5.12~~5.44 per share and ~~489,846~~396,760 SARs with ~~a weighted average~~ grant date fair value of $~~1.82~~1.97.

The grant date fair values of SARs awards are determined using a Black-Scholes pricing model. Assumptions utilized in the model are evaluated and revised, as necessary, to reflect market conditions and experience. The following table provides the weighted average assumptions used in determining the fair value of the ~~non-market~~non-performance based SARs awards granted during the ~~three-month period~~nine months ended ~~March 31, 2014:~~



		~~Three Months Ended~~
		~~March 31, 2014~~
~~Risk-free interest rate~~		~~0.69%~~
~~Expected life~~		~~3.5 years~~
~~Expected volatility~~		~~48.01%~~
~~Dividend yield~~		—%

The Company did not issue any SARs during the three months ended March 31, 2013. In February 2014, the Company’s chief executive officer was granted 188,165 market contingent SARs. The market contingent SARs have an exercise price of $5.10, a five year term to expiration, and a weighted-average fair value of $1.87. The fair value estimate of the market contingent SARs was calculated using a Monte Carlo Simulation model. The market contingent SARs are subject to a time-based vesting schedule, but will not vest unless and until certain additional, market-based conditions are satisfied: (1) with respect to the initial 36,496 market contingent SARs, which vest on a time-based schedule on the first anniversary of the date of grant, the closing price of the Company’s common stock is at least $7.65 per share for the average of 60 consecutive trading days anytime within five years from the grant date; (2) with respect to the next 64,460 market contingent SARs, which vest on a time-based schedule on the second anniversary of the date of grant, the closing price of the Company’s common stock is at least $10.20 per share for the average of 60 consecutive trading days anytime within five years from the grant date; and (3) with respect to the final 87,209 market contingent SARs, which vest on a time-based schedule on the third anniversary of the date of grant, the closing price of the Company’s common stock is at least $15.30 per share for the average of 60 consecutive trading days anytime within five years from the grant date. These stock prices represent premiums in excess of at least 50% of the closing stock price of the Company’s common stock on the date of grant.

~~The Company recognized~~ ~~$0.7 million~~September 30, 2013 and ~~$0.4 million of stock-based compensation expense during each of the~~2012: ~~three-month periods endedMarch 31, 2014~~ ~~and~~ ~~2013, respectively.~~


~~10.~~	~~INCOME TAXES~~

1211

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)



	Nine Months Ended
	September 30, 2013	September 30, 2012
Risk-free interest rate	0.33%	0.31%
Expected life (in years)	3.5	3.5
Expected volatility	49.80%	57.62%
Dividend yield	—%	—%

The Company recognized $0.4 million and $0.5 million of stock-based compensation expense for the three-month periods endedSeptember 30, 2013 and 2012, respectively, and $1.5 million for each of the nine-month periods ended September 30, 2013 and 2012.

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)


10.	INCOME TAXES

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position and the existence of a deferred tax liability related to indefinite lived intangibles, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on ~~(loss)~~ income from continuing operations and the effective tax rate for the ~~three-month~~three- and nine-month periods ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012:


	Three Months Ended						Three Months Ended						Nine Months Ended
	March 31,						September 30,						September 30,
	2014			2013			2013			2012			2013			2012
Provision for income tax	$	66		$	64		$	64		$	74		$	192		$	219
Effective income tax rate	(4.4		)%	2.9		%	(3.1		)%	(9.8		)%	(28.4		)%	(16.7		)%

Income tax expense for ~~each of~~ the ~~three-month~~nine-month periods ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012 was primarily due to state ~~taxes.~~and local taxes as the Company and its subsidiaries file separate income tax returns in numerous state and local jurisdictions.


11.	SEGMENT INFORMATION

The accounting policies of the segments are described in Note 1 of the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, ~~2013~~2012. Corporate charges are allocated to each of the reporting segments on the basis of total salary expense. Corporate charges include corporate headquarters costs and certain depreciation expenses. Certain corporate capital expenditures have not been allocated from the Sales Services segment to the other reporting segments since it is impracticable to do so.

Sales
Services

Marketing
Services
Product Commercialization Services Consolidated
Three months ended March 31, 2014:
Revenue $ 28,795
$ 1,003
$ 2,980
$ 32,778
Operating income (loss) $ 50
$ (1,323 ) $ (224 ) $ (1,497 )
Capital expenditures $ 514
$ —
$ —
$ 514
Depreciation expense $ 207
$ 229
$ 21
$ 457

Three months ended March 31, 2013:

Revenue $ 38,225
$ 1,541
$ 3,157
$ 42,923
Operating income (loss) $ 2,364
$ (683 ) $ 572
$ 2,253
Capital expenditures $ 169
$ 276
$ —
$ 445
Depreciation expense $ 234
$ 51
$ 3
$ 288


~~12.~~	~~DISCONTINUED OPERATIONS~~

On December 29, 2011 the Company entered into an agreement to sell certain assets of our Pharmakon business unit to Informed Medical Communications, Inc. (“Informed”) in exchange for potential future royalty payments and an ownership interest in Informed. In the fourth quarter of 2012, the Company wrote-off all of the assets related to the sale of Pharmakon to Informed as it believes that these assets have become impaired. On July 19, 2010, the Board approved closing the TVG business unit. The Company notified employees and issued a press release announcing this decision on July 20, 2010. The Consolidated Statements of Comprehensive Loss (Income) reflect the presentation of Pharmakon and TVG as discontinued operations in all periods presented.

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)



	Sales Services			Marketing Services			Product Commercialization Services		Consolidated
Three months ended September 30, 2013:
Revenue	$	30,748		$	781		$	2,731	$	34,260
Operating (loss) income	$	(1,316	)	$	(1,177	)	$	441	$	(2,052	)
Capital expenditures	$	290		$	402		$	—	$	692
Depreciation expense	$	296		$	46		$	3	$	345

Three months ended September 30, 2012:
Revenue	$	25,021		$	2,196		$	4,564	$	31,781
Operating (loss) income	$	(394	)	$	(1,326	)	$	964	$	(756	)
Capital expenditures	$	73		$	7		$	—	$	80
Depreciation expense	$	202		$	60		$	7	$	269

Nine months ended September 30, 2013:
Revenue	$	101,267		$	3,966		$	9,195	$	114,428
Operating income (loss)	$	31		$	(2,378	)	$	1,701	$	(646	)
Capital expenditures	$	545		$	1,103		$	—	$	1,648
Depreciation expense	$	746		$	145		$	31	$	922

Nine months ended September 30, 2012:
Revenue	$	68,539		$	8,061		$	14,667	$	91,267
Operating (loss) income	$	(1,524	)	$	(2,537	)	$	2,768	$	(1,293	)
Capital expenditures	$	513		$	15		$	—	$	528
Depreciation expense	$	575		$	195		$	43	$	813


12.	DISCONTINUED OPERATIONS

On December 29, 2011, we entered into an agreement to sell certain assets of our Pharmakon business unit to Informed in exchange for potential future royalty payments and a 1% ownership interest in Informed. The consolidated statement of operations reflects the presentation of Pharmakon as a discontinued operation in all periods presented.

On July 19, 2010, the Board approved closing the TVG business unit. The Company completed the closure of the TVG operations during the quarter ended September 30, 2010, including the completion of all active customer contracts. The financial statements reflect the presentation of TVG as a discontinued operation in all periods presented.

The table below presents the significant components of Pharmakon's and TVG’s results included in Loss from ~~discontinued operations~~Discontinued Operations in the Condensed Consolidated Statements of Operations and Comprehensive ~~Income (Loss)~~Loss for the ~~three-month~~three- and nine-month periods ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012.

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)


	Three Months Ended						Three Months Ended						Nine Months Ended
	March 31,						September 30,						September 30,
	2014			2013			2013			2012			2013			2012
Revenue, net	$	—		$	—		$	—		$	—		$	—		$	—
Loss from discontinued operations, before income tax	(31		)	(53		)	(27		)	(188		)	(27		)	(200		)
Provision for income tax	1			1			1			1			4			4
Loss from discontinued operations, net of tax	$	(32	)	$	(54	)	$	(28	)	$	(189	)	$	(31	)	$	(204	)

The major classes of assets and liabilities included in the Condensed Consolidated Balance Sheets for TVG and Pharmakon as of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012 are as follows:


	March 31, 2014		December 31, 2013		September 30, 2013		December 31, 2012
Current assets	$	—	$	—	$	23	$	14
Non-current assets	150		150		150		150
Total assets	$	150	$	150	$	173	$	164
Current liabilities	$	424	$	405	$	393	$	368
Non-current liabilities	540		619		768		1,006
Total liabilities	$	964	$	1,024	$	1,161	$	1,374

1415

PDI, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)


13.	INVESTMENT IN NON-CONTROLLED ENTITY ~~AND OTHER ARRANGEMENTS~~

In August 2013, PDI entered into ~~phase one of~~ a collaboration agreement with a privately held, emerging molecular diagnostics company (the Diagnostics Company) to commercialize its fully-developed, molecular diagnostic tests. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. Under the terms of ~~phase one of~~ the collaboration agreement, PDI paid an initial fee of $1.5 million and has ~~the ability to enter the second phase of the collaboration agreement in the form of a call~~received an option to purchase 100% of the outstanding common stock of the Diagnostics Company. PDI has recorded the initial fee as an investment in a non-controlled entity within Other current assets in the Consolidated Balance Sheets in accordance with ASC 325-20 Investments Other - Cost Method Investments.

The Company also has the option to contribute an additional $0.5 million for mutually agreed upon activities in furtherance of ~~collaboration~~commercialization efforts. The option price is dependent on the achievement of certain milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6.0 million if all milestones are achieved at their maximum levels. PDI can terminate the collaboration agreement if all milestones are not achieved ~~by August 2014~~within one year and would receive a $1.0 million termination ~~fee, leaving the Company with a maximum exposure of $0.5 million plus amounts contributed in furtherance of collaboration efforts.~~

fee. If all milestones are achieved ~~by August 2014~~within one year and PDI has not exercised its option, the Diagnostics Company can require PDI to exercise the option to purchase its outstanding common stock or terminate the collaboration agreement and pay PDI a termination fee of approximately $2.0 million. If PDI purchases the outstanding common stock of the ~~Diagnostics~~Diagnostic Company, in addition to the option price based on the achievement of milestones, beginning in 2015, PDI would pay a royalty of 7% on annual net revenue up to $50.0 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100.0 million. For competitive reasons, the name of the Diagnostic Company and the specific focus area of the initial test to be commercialized are not being disclosed at this time.

During the period ended March 31, 2014, PDI loaned the Diagnostics Company approximately $0.6 million for the acquisition of a CLIA approved lab bearing a 4% interest rate. This loan is secured by the lab and the assets of the lab and is payable to PDI at the sooner of: May 31, 2015; the expiration or termination of the collaboration agreement between the parties; the acquisition of the Diagnostics Company by PDI; or default by the Diagnostics Company. PDI has recorded the ~~loan receivable~~initial fee as an investment in a non-controlled entity within Other current assetsin the Condensed Consolidated Balance ~~Sheets.~~

Sheets in accordance with ASC 325-20 Investments Other ~~Arrangements~~- Cost Method Investments.


14.	SUBSEQUENT EVENT

In October 2013, the Company entered into ~~phase one of~~ a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by ~~Transgenomic, in the United States.~~Transgenomic. Under the terms of the strategic collaboration agreement, ~~PDI~~the Company will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will ~~pay~~bear the cost of their respective expenses and will split profit on a formula basis. IfIn addition, the Company ~~moves to the second phase of the collaboration agreement, PDI may~~will provide Transgenomic with funding support of up to ~~$3.0~~3.0 million, principally to ~~finance~~mitigate working capital ~~requirements for the product. Through March 31, 2014, the Company has not provided any funding to Transgenomic.~~requirements.

~~PDI's costs related to both of these agreements are expensed in the Company's PC Services segment and reflected in~~ ~~Cost of sales~~ or ~~Selling, general and administrative expenses~~ ~~in the Consolidated Statement of Comprehensive Loss, depending upon the underlying nature of the expenses incurred.~~

~~PDI, Inc.~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q/A contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934 (the Exchange Act). Statements that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,” “may,” “will” or similar words and expressions. These forward-looking statements are contained throughout this Form 10-Q/A.

Forward-looking statements are only predictions and are not guarantees of future performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. These statements are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

Changes in outsourcing trends or a reduction in promotional, marketing and sales expenditures in the pharmaceutical, biotechnology and healthcare industries;

Our customer concentration risk in light of continued consolidation within the pharmaceutical industry and our current business development opportunities;

PDI, Inc.

Early termination of a significant services contract, the loss of one or more of our significant customers or a material reduction in service revenues from such customers;

Our ability to obtain additional funds in order to implement our business model and strategy;

Our ability to successfully identify, complete and integrate any future acquisitions or successfully complete and integrate our diagnostic commercialization opportunities and the effects of any such items on our revenues, profitability and ongoing business;

Our ability to meet performance goals in incentive-based arrangements with customers;

Our ability to successfully negotiate contracts with reasonable margins and favorable payment terms;

Competition in our industry;

Our ability to attract and retain qualified sales representatives and other key employees and management personnel;

Product liability claims against us;

Failure of third-party service providers to perform their obligations to us;

Volatility of our stock price and fluctuations in our quarterly and annual revenues and earnings;

Failure of, or significant interruption to, the operation of our information technology and communication systems; and

The results of any future impairment testing for goodwill and other intangible assets.

Please see Part I – Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2013~~2012, as well as other documents we file with the United States Securities and Exchange Commission (SEC) from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements discussed in this Form 10-Q/A. Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

OVERVIEW

~~PDI, Inc.~~

We are a leading provider of outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the United States. We are a leading provider of outsourced sales teams that target healthcare providers, offering a range of complementary sales support services designed to achieve our customers' strategic and financial product objectives. In addition to outsourced sales teams in the United States, we also provide other promotional services including clinical educator services, digital communications ~~teledetailing~~ and ~~through our Interpace BioPharma business unit, we provide pharmaceutical, biotechnology, medical device and diagnostics clients with full-service product commercialization solutions.~~teledetailing. Combined, our services offer customers a range of both personal and non-personal promotional options for the commercialization of their products throughout their lifecycles, from development through maturity. We provide innovative and flexible service offerings designed to drive our customers' businesses forward and successfully respond to a continually changing market. Our services provide a vital link between our customers and the medical community through the communication of product information to physicians and other healthcare professionals for use in the care of their patients. We provide these services through three reporting segments: Sales Services; Marketing Services; and Product Commercialization Services. These segments are described in detail under the captionDescription of Reporting Segments below.

Our business depends in large part on demand from the pharmaceutical, biotechnology and healthcare industries for outsourced promotional services. In recent years, this demand has been impacted by certain industry-wide factors affecting pharmaceutical, biotechnology and healthcare companies, including, among other things, pressures on pricing and access, successful challenges to intellectual property rights (including the introduction of competitive generic products), a strict regulatory environment, decreased pipeline productivity and a slow-down in the rate of approval of new products by the United States Food and Drug Administration (FDA). Additionally, a number of pharmaceutical companies have made changes to their commercial models by reducing the internal number of sales representatives. A significant portion of our revenue is derived from our sales force arrangements with large pharmaceutical companies, and we have therefore benefited from cost control measures implemented by these companies and their resultant increased reliance on outsourced promotional services. However, we are also experiencing fluctuations in revenue due to certain clients renewing with a smaller salesforce and the expiration of certain other contracts due to the timing of new business and the variable nature of our business. We believe that we will continue to experience a high degree of customer concentration and this trend may continue as a result of the continuing consolidation within the pharmaceutical industry.

With our proven record of outsourced promotional services expertise, we took action in 2013 on our stated strategy of searching for product in-licensing, acquisition and partnering opportunities that could

PDI, Inc.

In order to add more predictable, higher growth, higher margin business that can ~~reduce~~smooth the natural volatility of our current core businesses, and at the same time leverage the ~~breadth~~breath of our installed infrastructure and strength of our core commercialization ~~capabilities. Through our Interpace Diagnostics entity,~~capabilities we have recently announced a strategy ~~focused on becoming~~to become a leading commercialization company for the molecular diagnostics industry via in-licensing, acquiring or ~~partnering.~~partnering through our Interpace BioPharma business unit. The molecular diagnostics industry is highly fragmented with numerous strong science-based companies that have developed clinically important tests which are ready or near ready for market. A vast majority of these companies have very limited experience bringing a test to market and many of them do not have the capital to build an infrastructure to effectively commercialize their test. Due to their complexity, most molecular diagnostic tests require a specialized go-to-market strategy, which includes messaging to physicians and potentially patients, similar to launching of a new drug in the pharmaceutical market. Developing and delivering these kinds of messages, fully leveraging our extensive commercial infrastructure in an impactful, innovative and ROI centric manner is one of our strengths. Given our proven core sales and marketing and full commercialization capabilities, we believe this is a natural extension for us and the strength of these core capabilities, our installed infrastructure and the ability to gain synergies significantly mitigates the risks associated with this strategy.

In October 2013, we entered into ~~phase one of~~ a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by ~~Transgenomic, in the United States.~~Transgenomic. Under the terms of the strategic collaboration agreement, we will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will ~~pay~~bear the cost of their respective expenses and will split profit on a formula basis. IfIn addition, we ~~enter into phase two of the collaboration agreement, we may~~will provide Transgenomic with funding support of up to $3.0 million, principally to ~~finance~~mitigate working capital requirements.

In August 2013, we entered into ~~phase one of~~ a collaboration agreement with a privately held, emerging molecular diagnostics company (the Diagnostics Company) to commercialize their molecular diagnostic tests. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. The initial test to be commercialized is fully developed. Under the terms of the collaboration agreement, we paid an initial fee of $1.5 million and have received an option to purchase the outstanding common stock of the Diagnostics Company. The option price is dependent on the achievement of certain milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6 million if all milestones are achieved at their maximum ~~levels and we enter into phase two of the collaboration agreement.~~levels. We can terminate the collaboration agreement if all milestones are not achieved ~~by August 2014~~within one year and

~~PDI, Inc.~~

would receive a $1.0 million termination fee. If all milestones are achieved ~~by August 2014~~within one year and we have not exercised our option, the Diagnostics Company can require us to exercise the option to purchase the outstanding stock of the Diagnostics Company or terminate the collaboration agreement and pay us a termination fee of approximately $2.0 million. If we purchase the ~~Diagnostics~~Diagnostic Company, in addition to the option price based on the achievement of milestones, beginning in 2015, we would pay a royalty of 7% on annual net revenue up to $50 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100 million. For competitive reasons, the name of the Diagnostic Company and the specific focus area of the initial test to be commercialized are not being disclosed at this time.

In December 2011, we entered into an agreement to sell certain assets of our Pharmakon business unit to Informed in exchange for potential future royalty payments with a fair value of $0.4 million and a 1% ownership interest in Informed valued at $0.1 million. Net of the aforementioned consideration, we recorded a charge of approximately $7.5 million. In the fourth quarter of 2012, we wrote-off all of the assets related to the sale of Pharmakon to Informed as we believe that these assets have become impaired. See Note 18, Discontinued Operations, to the audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2012 for additional details.

In August 2011, we announced the formation of our Interpace BioPharma business unit. Interpace BioPharma provides pharmaceutical, biotechnology, medical device and diagnostics clients with full-service product commercialization solutions. These services include full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. This unit currently has one contract, the revenue and expenses of which are included in the Product Commercialization Services segment.

In March 2011, we announced the launch of a business unit within our Sales Services segment, EngageCE. EngageCE provides clinical educator services to our customers. The goal of clinical educators is to work with healthcare providers in the management of chronic diseases in order to optimize patient care and outcomes. We believe that the clinical educator services provided via EngageCE complements traditional sales force efforts and enhances our offerings. EngageCE operates autonomously from the other business units in the Sales Service segment.

In November 2010, we acquired 100% of the membership interest in Group DCA, a privately held interactive digital communications company serving the pharmaceutical, biotechnology and healthcare industries. Based in Parsippany, New Jersey,

PDI, Inc.

Group DCA leverages the strength of the Internet, multimedia, tablet PCs, iPads, mobile devices, dimensional direct mail and its proprietary software, DIAGRAM^™, to deliver non-personal selling solutions via interactive communications exchanges that accommodate the schedules of healthcare providers. Group DCA's proprietary software also yields meaningful response data that allows customers the opportunity to better understand the needs and opinions of their audiences and, in turn, the opportunity to market to their audiences more effectively. With the combination of PDI's traditional outsourced promotional services and Group DCA's online interactive engagements, HCP communications, Sales Rep digital selling tools, patient education, and other digital communications, we are better positioned to offer customers increased insight and greater engagement, resulting in integrated information and more impactful messages being delivered to healthcare providers across multiple communication channels.

We paid cash (net) of approximately $23.9 million for Group DCA, of which $1.3 million was placed in escrow. The escrow amount of $1.3 million was paid out during the quarter ended June 30, 2012. The purchase agreement also provided for the former members of Group DCA to earn up to an additional $30.0 million from the date of acquisition through December 31, 2012. These payouts were to be based on Group DCA's achievement of revenue and gross profit metrics and ranged up to: $5.0 million in the period ended December 31, 2010; and $12.5 million in each of the years ending December 31, 2011 and 2012. The metrics for payments related to the periods ended December 31, 2010 were not achieved. In November 2011, we announced the retirement of the Group DCA co-CEOs as of December 31, 2011 and announced that we amended the Group DCA purchase agreement to negotiate a buy out of the contingent earn-out fee. Under the amendment, we paid $3.4 million to buy out the contingent earn-out fee under the purchase agreement in 2012. Pursuant to their respective retirement agreements, we paid $0.3 million to each of the co-CEOs in October 2013.

During our 2012 annual impairment tests of goodwill and indefinite-lived intangible assets and our review of the recoverability of finite-lived intangible assets, we identified potential impairment and subsequently determined that these Group DCA business unit assets were impaired and recognized an impairment charge of $22.8 million. See Note 7, Goodwill and Other Intangible Assets, to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 for further information.

While we recognize that there is currently significant volatility in the markets in which we provide services, we believe there are opportunities for growth in our Sales Services, Marketing Services and Product Commercialization Services businesses. These businesses provide our customers with the flexibility to successfully respond to a constantly changing market and a means of controlling costs through promotional outsourcing partnerships. In particular, we believe that the significant reduction in the number of pharmaceutical sales representatives within the industry during the past few years is placing increasing demands on our customers' product portfolios and therefore we expect the market share penetration of outsourced sales organizations to increase in order to address these needs. We have recently intensified our focus on strengthening all aspects of the core outsourced pharmaceutical sales teams business that we believe will most favorably position PDI as the leading outsourced promotional services organization in the United States. We believe our focus has led to the significant level of new business wins we experienced in 2012. In addition, we continue to diligently evaluate the risks and rewards of opportunities within our PC Services segment as they arise, while enhancing future value-added service offerings, as well as continue to evaluate acquisitions that will enhance our current service offerings and provide new business opportunities.

DESCRIPTION OF REPORTING SEGMENTS

For the quarter ended ~~March 31, 2014~~September 30, 2013, our three reporting segments were as follows:

▪Sales Services, which ~~consists~~is comprised of the following business units:

Dedicated Sales Teams;

Established Relationship ~~Teams;~~Teams (ERT) (formerly known as Shared Sales Teams); and

EngageCE.

▪Marketing Services, which ~~consists~~is comprised of the following business units:

Group DCA; and

Voice.

▪Product Commercialization Services (PC Services) which ~~consists~~is comprised of ~~efforts related to our collaboration agreements through Interpace Diagnostics and~~ the following business unit:

Interpace BioPharma.

PDI, Inc.

Selected financial information for each of these segments is contained in Note 11, Segment Information, to these interim financial statements and in the discussion under the caption Consolidated Results of Operations.

Nature of Contracts by Segment

Sales Services

Contracts within our Sales Services reporting segment consist primarily of detailing agreements and are nearly all fee-for-service arrangements. The term of these contracts is typically between one and ~~three~~two years. On occasion, certain contracts have terms that are modestly shorter or longer due to the seasonal nature of the products or at the request of the customer. All agreements, whether or not specifically provided for by terms within the contract, may be renewed or extended upon mutual agreement of the parties. Renewed or extended contracts may include revised terms for provisions such as pricing, penalties, incentives and performance metrics.

The majority of our Sales Services contracts are terminable by the customer without cause upon 30 ~~days’~~days' to 180 ~~days’~~days' prior written notice. Additionally, certain contracts include provisions mandating that such notice may not be provided prior to a pre-determined future date and also provide for termination payments if the customer terminates the agreement without cause. Typically, however, the total compensation provided by minimum service periods (otherwise referred to as minimum purchase obligations) and termination payments within any individual agreement will not fully offset the revenue we would have

~~PDI, Inc.~~

earned from fully executing the contract or the costs we may incur as a result of its early termination. The loss or termination of multiple Sales Services contracts could have a material adverse effect on our financial condition, results of operations and cash flow.

Our Sales Services contracts generally include standard mutual representations and warranties as well as mutual confidentiality and indemnification provisions, including product liability indemnification for our protection. Some of our contracts also include exclusivity provisions limiting our ability to promote competing products during the contract service period unless consent has been provided by the customer, and may also require the personnel we utilize to be dedicated exclusively to promoting the ~~customer’s~~customer's product for the term of the contract.

Some of our contracts, including contracts with significant customers of ours, may contain performance benchmarks requiring adherence to certain call plan metrics, such as a minimum amount of detailing activity to certain physician targets. Our failure to meet these benchmarks may result in specific financial penalties for us such as a reduction in our program management fee on our dedicated sales agreements, or a discount on the fee we are permitted to charge per detail on our established relationships agreements. Conversely, these same agreements generally include ~~risk-based metrics which allow for~~ incentive payments that can be earned if our promotional activities generate results that meet or exceed agreed-upon performance targets.

All of our contracts provide for certain reimbursable out-of-pocket expenses such as travel, meals and entertainment or product sample distribution costs, for which we are reimbursed at cost by our customers. Certain contracts may also provide for reimbursement of other types of expenses depending upon the type of services we are providing to the customer.

Marketing Services

Our Marketing Services reporting segment is comprised of our Group DCA and Voice business units. Our Group DCA business unit enters into contracts and performs services with our major clients that fall under the scope of a master service agreement(s) (MSAs) or statements of work (SOWs) and typically have a term of one to three years. These MSAs, and in certain instances, SOWs, include standard representations and warranties, as well as confidentiality and indemnification obligations, and are generally terminable by the customer or us, without cause or prior written notice, for any reason. If the contract is terminated in any phase of its term, the customer is responsible for all work completed to date, plus the cost of any nonrefundable commitments we made on their behalf. There is significant customer concentration within our Group DCA business unit.

Our Voice business unit enters into contracts and performs services with our clients that generally take the form of MSAs and typically have a term of three months to one year.

PC Services

Our PC Services segment currently consists of our Interpace BioPharma business ~~unit and our two collaboration agreements entered into in connection with our strategy of becoming a leading commercialization company for the molecular diagnostics industry.~~

unit. In August 2011, Interpace BioPharma announced its first contract, a two and one-half year fee-for-service arrangement with a pharmaceutical company. This contract includes standard representations and warranties, as well as mutual confidentiality and indemnification obligations for our protection, and is terminable by the customer without cause upon 180 days prior written notice after the first anniversary of the contract effective date. This contract includes incentive payments that can be earned if our promotional activities generate results that meet or exceed agreed-upon performance targets. In addition, this contract provides for certain reimbursable out-of-pocket expenses such as travel, meals and entertainment and product sample distribution costs, for which we are reimbursed at cost by our customer.

PDI, Inc.

Due to the success of the program and to allow our customer to begin their long-term plan of building their own capabilities in the United States, this customer advised us that they wished to internalize selected commercialization activities as of October 1, 2012 and at the same time, extend other activities 6 months past the ~~original~~then current December 31, 2013 contract expiration date to June 30, 2014. The modified and extended contract resulted in an estimated ~~10% to 15%~~ net overall reduction ofto the ~~original~~then current $55 million ~~contract;~~contract of approximately 10% to 15%, however the contract is no longer terminable by the customer without cause. ~~We anticipate the contract will terminate on the June 30, 2014 contract expiration date.~~ During the ~~quarter~~period ended ~~March 31, 2014, this~~September 30, 2013, one customer accounted for all of the revenue in our PC Services segment.

~~We entered into two separate collaboration agreements~~This contract also includes exclusivity provisions limiting our ability to ~~commercialize molecular diagnostic tests in 2013. Under~~promote competing products during the ~~terms~~contract service period unless consent has been provided by the customer, and may also require the personnel we utilize to be dedicated exclusively to promoting the customer's product for the term of the contract. This agreement also includes incentive payments that can be earned if our ~~October 2013 strategic collaboration agreement with Transgenomic, we will be responsible for all U.S.-based marketing~~promotional activities generate results that meet or exceed agreed-upon performance targets.

~~PDI, Inc.~~

~~and promotion of CardioPredict™. We will bear the cost of our expenses only and will split profit on a formula basis.~~ In addition, this contract provides for certain reimbursable out-of-pocket expenses such as travel, meals and entertainment and product sample distribution costs, for which we ~~may provide Transgenomic with funding support of up to $3.0 million principally to finance working capital requirements for the product. Under the terms of~~are reimbursed at cost by our August 2013 collaboration agreement with a privately held, emerging molecular diagnostics company (the Diagnostics Company), if we enter into the second phase of collaboration arrangement, we will be responsible for the full commercialization of their molecular diagnostic tests. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. Under the terms of the collaboration agreement, we paid an initial fee of $1.5 million and have the ability to enter the second phase of the collaboration agreement in the form of a call option to purchase the outstanding common stock of the Diagnostics Company. The option price is dependent on the achievement of certain milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6 million if all milestones are achieved at their maximum levels. We can terminate the collaboration agreement if all milestones are not achieved by August 2014 and would receive a $1.0 million termination fee. If all milestones are achieved by August 2014 and we have not exercised our option, the Diagnostics Company can require us to exercise the option to purchase the outstanding stock of the Diagnostics Company or terminate the collaboration agreement and pay us a termination fee of approximately $2.0 million. If we purchase the Diagnostics Company, in addition to the option price based on the achievement of milestones, beginning in 2015, we would pay a royalty of 7% on annual net revenue up to $50 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100 million.

customer.

CONSOLIDATED RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, certain statements of operations data as a percentage of revenue, net. The trends illustrated in this table may not be indicative of future results.


	Three Months Ended				Three Months Ended				Nine Months Ended
	March 31,				September 30,				September 30,
	2014		2013		2013		2012		2013		2012
Revenue, net	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services	84.4	%	80.3	%	86.3	%	81.3	%	82.5	%	78.2	%
Gross profit	15.6	%	19.7	%	13.7	%	18.7	%	17.5	%	21.8	%

Compensation expense	10.8	%	9.7	%	12.3	%	12.8	%	11.6	%	13.9	%
Other selling, general and administrative expenses	9.4	%	4.8	%	7.3	%	8.2	%	6.4	%	9.2	%
Total operating expenses	20.2	%	14.5	%	19.7	%	21.1	%	18.1	%	23.2	%
Operating (loss) income	(4.6	)%	5.2	%
Operating loss					(6.0	)%	(2.4	)%	(0.6	)%	(1.4	)%

Other expense, net	(0.1	)%	—	%	—	%	—	%	—	%	—	%
(Loss) income from continuing operations before income tax	(4.6	)%	5.2	%
Loss from continuing operations before income tax					(6.0	)%	(2.4	)%	(0.6	)%	(1.4	)%
Provision for income tax	0.2	%	0.1	%	0.2	%	0.2	%	0.2	%	0.2	%
(Loss) income from continuing operations	(4.8	)%	5.1	%
Loss from continuing operations					(6.2	)%	(2.6	)%	(0.8	)%	(1.7	)%

~~Results of Continuing Operations for the Quarter Ended~~ ~~March 31, 2014~~ ~~Compared to the Quarter Ended~~ ~~March 31, 2013~~

Overview

We operate in three business segments: Sales Services; Marketing Services; and PC Services. While our quarter to quarter results can be impacted by the start or completion/termination of contracts we believe that long term trends in the pharmaceutical industry will result in a higher level of outsourcing of the types of services we provide.

Our revenue and profitability depend to a great extent on our relationships with a limited number of large pharmaceutical companies. For the nine-month period endedSeptember 30, 2013, we had two customers that accounted for approximately 47.4% and 19.6% of our service revenue. We are inlikely to continue to experience a high degree of customer concentration, particularly if there is further consolidation within the ~~pursuit~~pharmaceutical industry. The loss or significant reduction of ~~adding more predictable, higher growth, higher margin~~ business ~~that will eliminate natural volatility~~from any of our ~~current core businesses,~~significant customers, or a decrease in demand for our services, could have a material adverse effect on our financial condition and ~~at the same time leverage the breadth~~results of our installed infrastructure and the strength of our core commercialization capabilities through our recently announced strategy to become a leading commercialization company for the molecular diagnostics industry via in-licensing, acquiring or partnering through our Interpace Diagnostics entity. The molecular diagnostics industry is highly fragmented with numerous strong science-based companies that have developed clinically important tests which are ready oroperations.

2021

PDI, Inc.

~~near ready~~Results of Continuing Operations for ~~market. A vast majority of these companies have very limited experience bringing a test~~the Quarter Ended September 30, 2013 Compared to ~~market and many of them do not have~~ the capital to build an infrastructure to effectively commercialize their test. Due to their complexity, most molecular diagnostic tests require a specialized go-to-market strategy, which includes messaging to physicians and potentially patients, similar to launching of a new drug in the pharmaceutical market. Developing and delivering these kinds of messages, fully leveraging our extensive commercial infrastructure in an impactful, innovative and ROI centric manner is one of our strengths. Given our proven core sales and marketing and full commercialization capabilities, we believe that this is a natural extension for us and the strength of our core capabilities, installed infrastructure and the ability to gain synergies significantly mitigates the risks associated with this strategy.Quarter Ended September 30, 2012


Revenue, net (in thousands)	Three Months Ended									Three Months Ended
	March 31,									September 30,
	2014		2013		Change ($)			Change (%)		2013		2012		Change ($)			Change (%)
Sales Services	$	28,795	$	38,225	$	(9,430	)	(24.7	)%	$	30,748	$	25,021	$	5,727		22.9	%
Marketing Services	1,003		1,541		(538		)	(34.9	)%	781		2,196		(1,415		)	(64.4	)%
PC Services	2,980		3,157		(177		)	(5.6	)%	2,731		4,564		(1,833		)	(40.2	)%
Total	$	32,778	$	42,923	$	(10,145	)	(23.6	)%	$	34,260	$	31,781	$	2,479		7.8	%

Consolidated revenue, net (revenue) for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased~~increased by $~~10.1~~2.5 million, or ~~23.6%~~7.8%, to $~~32.8~~34.3 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. ~~The decrease~~This increase was ~~primarily a result~~ofattributable to the ~~expiration or reduction of contracts being executed~~significant 2012 new contract wins in our Sales Services segment being executed in ~~2014 exceeded the contracts entered.~~2013.

Revenue in our Sales Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased~~increased by $~~9.4~~5.7 million, or ~~24.7%~~22.9%, to $~~28.8~~30.7 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. The ~~decrease~~increase in Sales Services revenue, as mentioned above, was primarily due to the ~~expiration or reduction of contracts~~significant new dedicated contract wins in 2012 being executed in ~~2014 exceeded the contract entered into.~~2013, partially offset by a decline in ERT revenue.

Revenue in our Marketing Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased $~~0.5~~$1.4 million, or ~~34.9%~~64.4%, to $~~1.0~~0.8 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. ~~This~~The decrease was primarily due to ~~a decline in revenue~~fewer contract signings at our Group DCA business ~~unit as a result of fewer contract signings.~~unit.

Revenue in our PC Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 was $~~3.0~~2.7 million, ~~slightly~~$1.8 million lower than the ~~first~~second quarter of ~~2013.~~2012 due to the internalization of selected commercialization activities by our customer as of October 1, 2012.


Cost of services (in thousands)	Three Months Ended									Three Months Ended
	March 31,									September 30,
	2014		2013		Change ($)			Change (%)		2013		2012		Change ($)			Change (%)
Sales Services	$	24,052	$	30,906	$	(6,854	)	(22.2	)%	$	26,710	$	20,864	$	5,846		28.0	%
Marketing Services	1,171		1,157		14			1.2	%	791		1,775		(984		)	(55.4	)%
PC Services	2,446		2,387		59			2.5	%	2,063		3,203		(1,140		)	(35.6	)%
Total	$	27,669	$	34,450	$	(6,781	)	(19.7	)%	$	29,564	$	25,842	$	3,722		14.4	%

Consolidated cost of services for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased~~increased by $~~6.8~~3.7 million, or ~~19.7%~~14.4%, to $~~27.7~~29.6 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. This ~~decrease~~increase was primarily due to ~~the expiration or reduction of~~ contracts within our Sales Services segment ~~being~~that were won in 2012 and executed in ~~2014.~~2013, partially offset by a reduction of costs in our PC Services and Marketing Services segments.

Cost of services in our Sales Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased~~increased by $~~6.9~~5.8 million, or ~~22.2%~~28.0%, to $~~24.1~~26.7 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. This ~~decrease~~increase was directly attributable to the ~~decrease~~increase in revenue from the 2012 contract wins discussed above.

Cost of services in our Marketing Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~remained essentially flat at~~decreased by $~~1.2~~1.0 million, or 55.4%, to $0.8 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. This decrease was attributable to the decline in revenue discussed above and the actions we have taken to lower the cost structure in our Group DCA business unit in an effort to realign the cost structure with the current level of business.

Cost of services in our PC Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~increased~~decreased $~~0.1~~1.1 million, or ~~2.5%~~35.6%, to $~~2.4~~2.1 million, compared to the quarter ended~~March 31, 2013~~September 30, 2012. This decrease was directly attributable to the decline in revenue discussed above.

2122

PDI, Inc.


Gross profit (in thousands)	Gross profit (in thousands)																					Gross profit (in thousands)
Three Months Ended		Sales			% of		Marketing			% of		PC			% of					% of			Sales			% of		Marketing			% of		PC			% of					% of
March 31,		Services			Sales		Services			Sales		Services			Sales		Total			Sales
2014		$	4,743		16.5	%	$	(168	)	(16.7	)%	$	534		17.9	%	$	5,109		15.6	%
September 30,																							Services			Sales		Services			Sales		Services			Sales		Total			Sales
2013		7,319			19.1	%	384			24.9	%	770			24.4	%	8,473			19.7	%		$	4,038		13.1	%	$	(10	)	(1.3	)%	$	668		24.5	%	$	4,696		13.7	%
2012																							4,157			16.6	%	421			19.2	%	1,361			29.8	%	5,939			18.7	%
Change		$	(2,576	)			$	(552	)			$	(236	)			$	(3,364	)				$	(119	)			$	(431	)			$	(693	)			$	(1,243	)

Consolidated gross profit for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased by $~~3.4~~1.2 million, or ~~39.7%~~20.9%, to $~~5.1~~4.7 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. The change in consolidated gross profit was primarily attributable to the ~~decrease~~decreases in revenue inwithin our ~~Sales~~PC Services ~~segment~~ and ~~margin pressures from competitive pricing pressures.~~Marketing Services segments.

The gross profit percentage in our Sales Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased to ~~16.5%~~13.1%, from ~~19.1%~~16.6% in the quarter ended ~~March 31, 2013~~September 30, 2012. ~~This~~The decrease was ~~primarily~~ due to new business being won with lower profit margins from competitive pricing ~~pressures.~~pressures and the reduction in revenue in our ERT business unit over its fixed management costs.

The gross profit percentage in our Marketing Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased to ~~a negative~~ ~~16.7%~~(1.3)%, from ~~24.9%~~19.2% in the quarter ended ~~March 31, 2013~~September 30, 2012. ~~This decrease was~~The negative gross profit percentage for the quarter is primarily ~~due~~attributable to ~~the impact of~~ certain fixed ~~costs~~cost of services over a lower revenue ~~base and the business unit not being able to reduce its cost structure in proportion with the decline in revenue due to the announced launch of its new product, PD One™.~~base.

The gross profit percentage in our PC Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased to ~~17.9%~~24.5%, from ~~24.4%~~29.8% in the quarter ended~~March 31, 2013~~September 30, 2012. The decrease ~~in gross profit percentage~~ was primarily due to the ~~expenses related to a collaboration agreement for~~change in profitability on the mix of services performed after our ~~molecular diagnostic strategy in Interpace Diagnostics.~~customer internalized certain activities as of October 1, 2012.


Compensation expense (in thousands)	Compensation expense (in thousands)																				Compensation expense (in thousands)
Three Months Ended		Sales			% of		Marketing			% of		PC		% of					% of			Sales		% of		Marketing			% of		PC			% of				% of
March 31,		Services			Sales		Services			Sales		Services		Sales		Total			Sales
2014		$	2,930		10.2	%	$	456		45.5	%	$	155	5.2	%	$	3,541		10.8	%
September 30,																						Services		Sales		Services			Sales		Services			Sales		Total		Sales
2013		3,389			8.9	%	652			42.3	%	114		3.6	%	4,155			9.7	%		$	3,441	11.2	%	$	670		85.8	%	$	120		4.4	%	$	4,231	12.3	%
2012																						3,100		12.4	%	753			34.3	%	222			4.9	%	4,075		12.8	%
Change		$	(459	)			$	(196	)			$	41			$	(614	)				$	341			$	(83	)			$	(102	)			$	156

Consolidated compensation expense for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased by~~increased $~~0.6~~0.2 million, to $~~3.5~~4.2 million, as compared to the quarter ended ~~March 31, 2013~~September 30, 2012. This increase was primarily due to severance of $0.3 million. As a percentage of consolidated revenue, consolidated compensation expense ~~increased~~decreased to ~~10.8%~~12.3% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~9.7%~~12.8% for the quarter ended ~~March 31, 2013~~September 30, 2012~~, due primarily to the~~. The decrease in ~~quarter-over-quarter revenue.~~consolidated compensation expense as a percent of consolidated revenue was a result of the increase in consolidated revenue more than offsetting the increase in consolidated compensation costs.

Compensation expense in our Sales Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~decreased $0.5 million, or 13.5%,~~increased to ~~$2.9~~$3.4 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. This increase was primarily due to the severance mentioned above. As a percentage of segment revenue, compensation expense ~~increased~~decreased ~~1.3%~~1.2%, to ~~10.2%~~11.2% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~8.9%~~12.4% for the quarter ended ~~March 31, 2013~~September 30, 2012, primarily due to the ~~decrease~~increase in Sales Services segment revenue.

Compensation expense in our Marketing Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 decreased by $~~0.2~~0.1 million, to $~~0.5~~0.7 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012. As a percentage of segment revenue, compensation expense increased ~~3.2%~~51.5%, to ~~45.5%~~85.8% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~42.3%~~34.3% for the quarter ended ~~March 31, 2013~~September 30, 2012. The increase in segment compensation expense as a ~~percentage~~percent of segment revenue was a result of the decrease in segment revenue ~~within the segment~~ more than offsetting the decrease in segment compensation costs.

Compensation expense in our PC Services segment for both periods ~~is primarily attributable to~~represents the allocated ~~costs~~cost of corporate support ~~activities in each of the respective periods.~~activities.

2223

PDI, Inc.


Other selling, general and administrative expenses (in thousands)	Other selling, general and administrative expenses (in thousands)																	Other selling, general and administrative expenses (in thousands)
Three Months Ended		Sales		% of		Marketing		% of		PC		% of				% of			Sales		% of		Marketing			% of		PC			% of					% of
March 31,		Services		Sales		Services		Sales		Services		Sales		Total		Sales
2014		$	1,763	6.1	%	$	699	69.7	%	$	603	20.2	%	$	3,065	9.4	%
September 30,																			Services		Sales		Services			Sales		Services			Sales		Total			Sales
2013		1,566		4.1	%	415		26.9	%	84		2.7	%	2,065		4.8	%		$	1,913	6.2	%	$	497		63.6	%	$	107		3.9	%	$	2,517		7.3	%
2012																			1,451		5.8	%	994			45.3	%	175			3.8	%	2,620			8.2	%
Change		$	197			$	284			$	519			$	1,000				$	462			$	(497	)			$	(68	)			$	(103	)

Consolidated other selling, general and administrative expenses for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~increased by $1.0~~ ~~million, to $3.1~~ ~~million,~~remained essentially flat when compared to the quarter ended ~~March 31, 2013~~September 30, 2012. ~~The increase was driven by $0.6 million in costs related to collaboration agreement efforts for molecular diagnostic tests and $0.3 million of costs to early terminate the Group DCA facility lease.~~ As a percentage of consolidated revenue, consolidated other selling, general and administrative expenses ~~increased~~decreased to ~~9.4%~~7.3% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~4.8%~~8.2% in the quarter ended ~~March 31, 2013~~September 30, 2012, due primarily to the increase in consolidated ~~other selling, general and administrative expenses and the decrease in revenue discussed above.~~revenue.

Other selling, general and administrative expenses in our Sales Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 increased ~~slightly,~~ by $~~0.2~~0.5 million, to $~~1.8~~1.9 million, compared to the quarter ended ~~March 31, 2013~~September 30, 2012, primarily due to ~~the~~a $0.5 million increase in allocated corporate ~~costs.~~legal and consulting costs related to entering into a collaboration agreement with a privately held, emerging molecular diagnostics company to commercialize their molecular diagnostic tests and entering into a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic. These collaboration agreements are part of our announced strategy of in-licensing, acquiring or partnering of products. As a percentage of segment revenue, other selling, general and administrative expenses increased ~~2.0%~~0.4%, to ~~6.1%~~6.2% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~4.1%~~5.8% in the quarter ended ~~March 31, 2013~~September 30, 2012, ~~primarily~~ due to the ~~decrease~~increase in ~~segment revenue.~~compensation expense.

Other selling, general and administrative expenses in our Marketing Services segment for the quarter ended ~~March 31, 2014~~September 30, 2013 ~~increased~~decreased by $~~0.3~~0.5 million compared to the quarter ended ~~March 31, 2013~~September 30, 2012., primarily due to the decreases in amortization expense and facility costs as well as a decrease in allocated corporate costs. Other selling, general and administrative expenses as a percentage of revenue increased ~~42.8%~~18.3%, to ~~69.7%~~63.6% for the quarter ended ~~March 31, 2014~~September 30, 2013, from ~~26.9%~~45.3% in the quarter ended ~~March 31, 2013~~September 30, 2012, due to the ~~increase in other selling, general and administrative costs and the segment~~ decrease in revenue.

Other selling, general and administrative expense in our PC Services segment for the ~~quarter~~quarters ended ~~March 31, 2014~~September 30, 2013 and September 30, 2012 of $~~0.6~~0.1 million and $0.2 million, respectively, represents ~~the costs related to collaboration agreement efforts for molecular diagnostic tests and~~ the allocated cost of corporate support activities. ~~Other selling, general and administrative expense for the~~ ~~quarter endedMarch 31, 2013~~ ~~of $0.1~~ ~~million represents the allocated cost of corporate support activities during that period.~~

Operating ~~(loss) income~~loss

We had an operating ~~loss~~losses of $~~1.5~~2.1 million and ~~operating income of $2.3~~$0.8 million for the quarters ended ~~March 31, 2014~~September 30, 2013 and ~~2013~~2012, respectively. The ~~decrease~~increase in operating ~~income~~loss was ~~primarily~~ due to lower margins on revenue, the ~~decrease~~increase in ~~revenue and gross profit within our Sales Services segment~~compensation expense and the ~~costs~~expenditures related to ~~collaboration efforts for molecular diagnostic tests.~~our strategy of in-licensing, acquiring or partnering of products.

Provision for income tax

We had income tax expense of approximately $0.1 million for each of the quarters ended ~~March 31, 2014~~September 30, 2013 and ~~March 31,~~September 30, 2012. Income tax expense for both quarters was primarily due to state and local taxes as we and our subsidiaries file separate income tax returns in numerous state and local jurisdictions.

Results of Continuing Operations for the Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012



Revenue, net (in thousands)	Nine Months Ended
	September 30,
	2013		2012		Change ($)			Change (%)
Sales Services	$	101,267	$	68,539	$	32,728		47.8	%
Marketing Services	3,966		8,061		(4,095		)	(50.8	)%
PC Services	9,195		14,667		(5,472		)	(37.3	)%
Total	$	114,428	$	91,267	$	23,161		25.4	%

Consolidated revenue for the nine months endedSeptember 30, 2013 increased by $23.2 million, or 25.4%, to $114.4 million, compared to the nine months endedSeptember 30, 2012. This increase was attributable to the significant 2012 new contract wins in our Sales Services segment being executed in 2013.

PDI, Inc.

Revenue in our Sales Servicessegment for the nine months endedSeptember 30, 2013 increased by $32.7 million, or 47.8%, to $101.3 million, compared to the nine months endedSeptember 30, 2012. The increase in Sales Servicesrevenue, as mentioned above, was primarily due to the significant new contract wins in 2012 being executed in 2013.

Revenue in our Marketing Services segment for the nine months endedSeptember 30, 2013 decreased by $4.1 million, or 50.8%, to $4.0 million, compared to the nine months endedSeptember 30, 2012. The decrease was primarily due to fewer contract signings at our Group DCA business unit.

Revenue in our PC Servicessegment for the nine months endedSeptember 30, 2013 was $9.2 million, $5.5 million lower than the nine months endedSeptember 30, 2012 due to the internalization of selected commercialization activities by our customer as of October 1, 2012.



Cost of services (in thousands)	Nine Months Ended
	September 30,
	2013		2012		Change ($)			Change (%)
Sales Services	$	84,658	$	55,401	$	29,257		52.8	%
Marketing Services	2,954		5,370		(2,416		)	(45.0	)%
PC Services	6,798		10,621		(3,823		)	(36.0	)%
Total	$	94,410	$	71,392	$	23,018		32.2	%

Consolidated cost of services for the nine months endedSeptember 30, 2013 increased by $23.0 million, or 32.2%, to $94.4 million, compared to the nine months endedSeptember 30, 2012. This increase was primarily due to contracts within our Sales Services segment that were won in 2012 and executed in 2013, partially offset by a reduction of costs in our PC Services and Marketing Services segments.

Cost of services in our Sales Servicessegment for the nine months endedSeptember 30, 2013 increased by $29.3 million, or 52.8%, to $84.7 million, compared to the nine months endedSeptember 30, 2012. This increase was directly attributable to the increase in revenue discussed above.

Cost of services in our Marketing Servicessegment for the nine months endedSeptember 30, 2013 decreased by $2.4 million, or 45.0%, to $3.0 million, compared to the nine months endedSeptember 30, 2012. The decrease was attributable to our emphasis on cost savings initiatives as we continue to right-size the structure of our Group DCA business unit in an effort to realign the cost structure with the current level of business and anticipated launch of future products.

Cost of services in our PC Servicessegment for the nine months endedSeptember 30, 2013 was $6.8 million, a decrease of $3.8 million compared to the nine months endedSeptember 30, 2012. This decrease was directly attributable to the decline in revenue discussed above.



Gross profit (in thousands)
Nine Months Ended	Sales		% of		Marketing			% of		PC			% of				% of
September 30,	Services		Sales		Services			Sales		Services			Sales		Total		Sales
2013	$	16,609	16.4	%	$	1,012		25.5	%	$	2,397		26.1	%	$	20,018	17.5	%
2012	13,138		19.2	%	2,691			33.4	%	4,046			27.6	%	19,875		21.8	%
Change	$	3,471			$	(1,679	)			$	(1,649	)			$	143

Consolidated gross profit for the nine months endedSeptember 30, 2013 increased by $0.1 million, or 0.7%, to $20.0 million, compared to the nine months endedSeptember 30, 2012. The change in consolidated gross profit was primarily attributable to the increase in revenue in our Sales Services segment partially offset by the declines in revenue in our Marketing Services and PC Services segments.

The gross profit percentage in our Sales Services segment for the nine months endedSeptember 30, 2013 decreased to 16.4%, from 19.2% in the nine months endedSeptember 30, 2012. This decrease was due to new business being won with lower profit margins resulting from competitive pricing pressures and the reduction in revenue in our Established Relationship Teams business unit relative its fixed management costs.

PDI, Inc.

The gross profit percentage in our Marketing Services segment for the nine months endedSeptember 30, 2013 decreased to 25.5%, from 33.4% in the nine months endedSeptember 30, 2012. The decrease in gross profit percentage was due to the decline in Group DCA revenue partially offset by the cost savings from actions we have taken to right-size the structure of the business unit.

The gross profit percentage in our PC Services segment for the nine months endedSeptember 30, 2013 remained relatively consistent at 26.1%, compared to the nine months endedSeptember 30, 2012.



Compensation expense (in thousands)
Nine Months Ended	Sales		% of		Marketing			% of		PC			% of				% of
September 30,	Services		Sales		Services			Sales		Services			Sales		Total		Sales
2013	$	10,935	10.8	%	$	1,980		49.9	%	$	385		4.2	%	$	13,300	11.6	%
2012	9,720		14.2	%	2,307			28.6	%	699			4.8	%	12,726		13.9	%
Change	$	1,215			$	(327	)			$	(314	)			$	574

Consolidated compensation expense for the nine months endedSeptember 30, 2013 increased by $0.6 million, to $13.3 million, as compared to the nine months endedSeptember 30, 2012. The increase was attributable to severance costs of $0.7 million. As a percentage of consolidated revenue, consolidated compensation expense decreased to 11.6% for the nine months endedSeptember 30, 2013, from 13.9% for the nine months endedSeptember 30, 2012, primarily due to the increase in consolidated revenue.

Compensation expense in our Sales Services segment for the nine months endedSeptember 30, 2013 increased by $1.2 million, to $10.9 million, as compared to the nine months endedSeptember 30, 2012. This increase was primarily attributable to allocated corporate bonus and severance costs. As a percentage of segment revenue, compensation expense decreased 3.4%, to 10.8% for the nine months endedSeptember 30, 2013, from 14.2% for the nine months endedSeptember 30, 2012, due to the increase in segment revenue.

Compensation expense in our Marketing Services segment for the nine months endedSeptember 30, 2013 decreased by $0.3 million, to $2.0 million, compared to the nine months endedSeptember 30, 2012. As a percentage of segment revenue, compensation expense increased 21.3%, to 49.9% for the nine months endedSeptember 30, 2013, from 28.6% for the nine months endedSeptember 30, 2012. The increase in segment compensation expense as a percent of segment revenue was a result of the decrease in revenue within the segment more than offsetting the decrease in compensation costs from our cost savings initiatives.

Compensation expense in our PC Servicessegment for the nine months endedSeptember 30, 2013 and the nine months endedSeptember 30, 2012 is attributable to the allocated costs of corporate support activities in each of the respective periods.



Other selling, general and administrative expenses (in thousands)
Nine Months Ended	Sales		% of		Marketing			% of		PC			% of					% of
September 30,	Services		Sales		Services			Sales		Services			Sales		Total			Sales
2013	$	5,643	5.6	%	$	1,410		35.6	%	$	311		3.4	%	$	7,364		6.4	%
2012	4,942		7.2	%	2,921			36.2	%	579			3.9	%	8,442			9.2	%
Change	$	701			$	(1,511	)			$	(268	)			$	(1,078	)

Consolidated other selling, general and administrative expenses for the nine months endedSeptember 30, 2013 decreased by $1.1 million, to $7.4 million, compared to the nine months endedSeptember 30, 2012. The decrease was primarily driven by a decrease in amortization expense of $0.7 million and a decrease in facility costs and depreciation expense of $0.6 million. As a percentage of consolidated revenue, consolidated other selling, general and administrative expenses decreased to 6.4% for the nine months endedSeptember 30, 2013, from 9.2% in the nine months endedSeptember 30, 2012, due to the increase in consolidated revenue and the decrease in consolidated other selling, general and administrative expenses.

Other selling, general and administrative expenses in our Sales Services segment for the nine months endedSeptember 30, 2013 increased by $0.7 million, to $5.6 million, compared to the nine months endedSeptember 30, 2012, primarily due to an increase in allocated corporate legal and consulting costs as we have intensified our announced strategy of in-licensing, acquiring or partnering of products. As a percentage of segment revenue, other selling, general and administrative expenses decreased 1.6%, to 5.6% for the nine months endedSeptember 30, 2013, from 7.2% in the nine months endedSeptember 30, 2012, due to the increase in segment revenue.

PDI, Inc.

Other selling, general and administrative expenses in our Marketing Services segment for the nine months endedSeptember 30, 2013 decreased by $1.5 million compared to the nine months endedSeptember 30, 2012, primarily due to a decrease in amortization expense of $0.7 million at Group DCA, a decrease in marketing costs of $0.3 million and a decrease in facility costs and depreciation expense of $0.2 million. Other selling, general and administrative expenses as a percentage of revenuedecreased 0.6%, to 35.6% for the nine months endedSeptember 30, 2013, from 36.2% in the nine months endedSeptember 30, 2012, due to the aforementioned decrease in Group DCA other selling, general and administrative expenses.

Other selling, general and administrative expense in our PC Servicessegment for the nine months endedSeptember 30, 2013 and nine months endedSeptember 30, 2012 is attributable to the allocated cost of corporate support activities in each of the respective periods.

Operating loss

We had operating losses of $0.6 million and $1.3 million for the nine months endedSeptember 30, 2013 and 2012, respectively. The decrease in the operating loss was primarily due to increased revenue with a lower gross profit percentage in our Sales Services segment and the overall reduction in operating expenses.

Provision for income tax

We had income tax expense of approximately $0.2 million for both the nine months endedSeptember 30, 2013 and 2012. Income tax expense for the ~~quarters~~nine months ended~~March 31, 2014~~September 30, 2013 and ~~March 31, 2013~~2012 was primarily due to state and local taxes as we and our subsidiaries file separate income tax returns in numerous state and local jurisdictions.

LIQUIDITY AND CAPITAL RESOURCES

As of ~~March 31, 2014~~September 30, 2013, we had cash and cash equivalents and short-term investments of approximately $~~38.0~~49.7 million and working capital of $~~29.7~~34.9 million, compared to cash and cash equivalents and short-term investments of approximately $~~45.7~~52.9 million and working capital of approximately $~~31.3~~35.2 million at December 31, ~~2013~~2012. As of ~~March 31, 2014~~September 30, 2013, we had no commercial debt.

For the ~~three-month~~nine-month period ended ~~March 31, 2014~~September 30, 2013, net cash provided by operating activities was $0.2 million, compared to $3.2 million of net cash used in operating activities ~~was $~~for the ~~6.5~~nine-month period endedSeptember 30, 2012 ~~million, compared to~~. The main components of net cash provided by ~~operations of $1.2~~ ~~million for~~operating activities during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2013. were a decrease in accounts receivable of $6.7 million and a decrease in other current assets of $2.3 million, offset by a net loss of $0.9 million, an increase in unbilled receivables of $4.7 million and a decrease in unearned contract revenue of $2.5 million. The increase in unbilled costs and decrease in accounts receivable is primarily due to changes of billing terms in contracts with our largest customer that resulted in an additional 25 days to 30 days to collect receivables for the majority of the amounts billed to this customer. The main components of cash used in operating activities during the ~~three-month~~nine-month period ended ~~March 31, 2014~~September 30, 2012 were a ~~net loss~~decrease in accrued expenses of $3.8 million as well as a decrease in long-term liabilities of $1.3 million. The decrease in accrued expenses was primarily driven by payments of severance and close-out costs associated with the sale of our Pharmakon business unit in December 2011, the right-sizing of the Group DCA business unit and a scheduled $1.5 million payment to buyout the contingent earn-out fee under the Group DCA purchase agreement. Partially offsetting these uses of cash were a $1.6 million ~~and an increase~~decrease in accounts receivable of $6.0 million due to the timing of certain payments from customers. The main components of cash provided by operating activities during the three-month period ended March 31, 2013 were net income of $2.1 million,unbilled receivables and a decrease in accounts receivable of ~~$1.1 million and an increase in current liabilities of $2.3 million, partially offset by an increase in unbilled costs of $5.1~~$1.4 million.

~~PDI, Inc.~~

As of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, we had $~~5.6~~6.6 million ~~million~~ and $~~8.0~~2.0 million of unbilled costs and accrued profits on contracts in progress, respectively. When services are performed in advance of billing, the value of such services is recorded as unbilled costs and accrued profits on contracts in progress. Normally all unbilled costs and accrued profits are earned and billed within 12 months from the end of the respective period. As of ~~March 31, 2014~~September 30, 2013 and December 31, ~~2013~~2012, we had $~~8.8~~12.0 million and $~~9.4~~14.5 million of unearned contract revenue, respectively. When we bill clients for services before they have been completed, billed amounts are recorded as unearned contract revenue and are recorded as income when earned.

For the ~~three-month~~nine-month period ended ~~March 31, 2014~~September 30, 2013, we had net cash used in investing activities of $~~1.1~~3.1 million compared to ~~$0.4~~$0.5 million of cash used in investing activities during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2012. The investment in the non-controlled entity in 2013~~, both related to capital expenditures. All~~ and the capital expenditures in both the nine-month period ended September 30, 2013 and 2012, were funded out of available cash.

For the ~~three-month periods~~nine-month period ended ~~March 31, 2014~~September 30, 2013 and ~~March 31, 2013~~September 30, 2012, net cash used in financing activities consisted of shares of our stock that were delivered to us and included in treasury stock for the payment of taxes resulting from the vesting of restricted stock.

PDI, Inc.

Going Forward

WePrimarily as a result of the impact of the significant multi-year contracts we won in 2012 totaling over $250 million, consolidated revenue in 2013 should be slightly more than the $126.9 million of consolidated revenue recorded in 2012, excluding any new business we win and revenue we earn in 2013. Assuming a reasonable level of new business wins, and no early termination of contracts, we now anticipate ~~2014~~consolidated 2013 revenue to be ~~a year during which~~20% higher than 2012 revenue. We do however anticipate gross profit percentage to be lower in recently won business resulting in 2013 gross profit being up to 5% below that of 2012. Before any investment in the business, we ~~continue~~anticipate combined 2013 compensation expense and other selling, general and administrative expenses to be marginally higher than 2012. With that said, in 2013, we expect to invest in several areas that will proactively leverage our core strengths, help differentiate ~~ourselves as we build off of~~us and intensify our ~~strategy~~competitive position in the market.

First, in order to add more predictable, higher growth, higher margin business that ~~could reduce~~can smooth the natural volatility of our current core ~~business. Last year~~businesses, and at the same time leverage the breath of our installed infrastructure and strength of our core commercialization capabilities we have recently announced ~~our strategic focus on becoming~~a strategy to become a leading commercialization company for the molecular diagnostics industry via in-licensing, acquiring or partnering. The molecular diagnostics industry is highly fragmented with numerous strong science-based companies that have developed clinically important tests which are ready or near ready for market. A vast majority of these companies have very limited experience bringing a test to market and many of them do not have the capital to build an infrastructure to effectively commercialize their test. Due to their complexity, most molecular diagnostic tests require a specialized go-to-market strategy, which includes messaging to physicians, and potentially patients, similar to launching of a new drug in the pharmaceutical market. Developing and delivering these kinds of messages, fully leveragingpartnering through our ~~extensive commercial infrastructure in an impactful, innovative and ROI centric manner is one of our strengths.~~Interpace BioPharma business unit. Given our proven core sales and marketing and full commercialization capabilities, we believe this is a natural extension for us and the strength of these core capabilities, our installed infrastructure and the ability to gain synergies significantly mitigates the risks associated with our product strategy. In connection with this ~~strategy.~~

strategy we have entered into two collaboration agreements since August 2013.

In ~~2014~~August 2013, we ~~will continue~~entered into a collaboration agreement with a privately held, emerging molecular diagnostics company (the Diagnostics Company) to ~~focus on~~commercialize its molecular diagnostic tests. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. The initial test to be commercialized is fully developed. Under the flawless execution of our customers’ programs in order to consistently deliver desired results. We recognize that our relationships with customers are dependent upon the quality of our performance and our ability to reach and engage their target audiences in a positive and meaningful manner. Through our core outsourced promotional services expertise, we must continue to provide innovative and flexible service offerings designed to drive our customers’ businesses forward and successfully respond to a continually changing market. We have, and will continue to, evolve our multi-channel promotional capabilities for many large pharmaceutical companies, a variety of emerging and specialty pharmaceutical and biotechnology companies as well as nutritional, diagnostic and other healthcare service providers.

~~Our primary strategic focus in 2014 is to determine the viability~~terms of the ~~two significant opportunities~~collaboration agreement, we paid an initial fee of $1.5 million and have received an option to ~~commercialize innovative molecular diagnostics tests,~~purchase 100% of the outstanding common stock of the Diagnostics Company. We also have the option to contribute an additional $0.5 million for mutually agreed upon activities in ~~Interpace Diagnostics, that we announced in the second half~~furtherance of ~~2013. In 2014, we will determine whether or not we will move into the second phase of either collaboration agreement. Our determination of moving forward with either of these collaboration agreements~~commercialization efforts. The option price is dependent ~~upon, among other things, commercial responsiveness to promotional efforts and~~on the achievement of certain ~~contractual milestones.~~milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6 million if all milestones are achieved at their maximum levels. We can terminate the collaboration agreement if all milestones are not achieved within one year and would receive a $1.0 million termination fee. If all milestones are achieved within one year and we have not exercised our option, the Diagnostics Company can require us to exercise the option to purchase the common stock of the Diagnostics Company or terminate the collaboration agreement and pay us a termination fee of approximately $2.0 million. If we purchase the Diagnostic Company, in addition to the option price based on the achievement of milestones, beginning in 2015, we would pay a royalty of 7% on annual net revenue up to $50 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100 million.

In October 2013, we entered into a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic. Under the terms of the strategic collaboration agreement, we will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will bear the cost of their respective expenses and will split profit on a formula basis. In addition, we will provide Transgenomic with funding support of up to $3.0 million, principally to mitigate working capital requirements.

To date we have used a portion of our cash for this strategy. We will ~~also~~ continue to ~~evaluate other commercialization~~use a portion of our cash, supplemented by additional financings, if necessary, to further this strategy as these opportunities ~~in the molecular diagnostics tests in 2014.~~may require up-front investment. We are actively seeking opportunities of this kind, and see the potential to complete ~~at least two additional opportunities during 2014 and multiple~~other deals over the longer term.

We ~~will continue to be diligent with but~~ are prepared to use a portion of our cash, supplemented by additional financings, if necessary, to continue this strategy as these two existing molecular diagnostic opportunities will require additional resources in 2014 and future opportunities may require up-front investment. We have begun, and will continue, to refocusrefocusing resources internally and ~~add~~will be adding both internal and external resources to move this strategy forward.

~~Our other strategic focus is~~Next, in order to further differentiate our core offerings, we have begun, and will continue, to make significant investment in systems and equipment in 2013 to advance these core offerings. We have developed strong capabilities in delivering integrated multi-channel offerings to health care providers. The breadth of these offerings and the ~~active promotion and marketing~~ability to integrate them in a return on investment focused manner has been a contributing factor in many of our ~~recently launched~~recent new business wins.

Finally, we are investing in and plan to launch a new product offering in our Group DCA business unit ~~product offering, PD One™. PD One™ is~~that will provide a ~~proprietary technology~~unique platform ~~aimed at expanding relationships between pharmaceutical and life science companies and~~for delivering sales representative driven, multi-channel communications to health care providers. The subscription-based platform enables clients to extend personal and brand interactions with physicians through a secure, professional networking platform that features direct messaging and dynamic content. The new platform complements PDI's award-winning companion site, ~~Medical Bag.com, a content-rich, multi-functional digital environment that receives more than 50,000 visits by medical professionals each month.~~ This offering ~~utilizes~~will initially lean on the Group DCA database of ~~approximately 400,000 physicians,~~over 300,000 physicians. This platform can be ~~leveraged~~utilized by our entire organization, ~~and will require ongoing support and enhancements.~~but has a much broader pharmaceutical industry application.

2428

PDI, Inc.

In total, we anticipate committing $4 million to $5 million to support these three areas in 2013, which does not include any amounts invested for product in-licensing, acquisitions or partnering. We expect that at least half of what we spend will be expensed in 2013. Through September 30, 2013, we have spent almost $3 million to support these areas. Our primary sources of liquidity are cash generated from our operations and available cash and cash equivalents. These sources of liquidity are needed to fund our working capital requirements, contractual obligations and estimated capital expenditures of approximately $2.0 million to $2.5 million in ~~2014.~~2013. We expect ~~our~~ working capital requirements to increase as ~~a result of~~other new customer contracts, similar to contracts with our largest customer, may generally ~~providing~~provide for longer than historical payment terms.

Considering the information provided above, we anticipate ~~2014~~full year 2013 operations will result in a loss and ~~2014~~full year 2013 cash flows will be negative. While we believe that our existing cash balances and expected cash flows generated from operations will be sufficient to meet our operating requirements beyond the next 12 months, we may require alternative forms of financing to achieve our strategic plan of product in-licensing, acquisitions or partnering.

2529

PDI, Inc.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

PDI is a smaller reporting company as defined by the disclosure requirements in Regulation S-K of the SEC and therefore not required to provide this information.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q/A. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.

Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in internal controls

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2630

PDI, Inc.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

~~None.~~We are currently a party to legal proceedings incidental to our business. As required, we have accrued our estimate of the probable costs for the resolution of these claims. While management currently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our business, financial condition or results of operations, litigation is subject to inherent uncertainties. Were we to settle a proceeding for a material amount or were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our business, financial condition or results of operations. Legal fees are expensed as incurred.

Item 1A. Risk Factors

~~There have been no material changes to~~PDI is a smaller reporting company as defined by the ~~risk factors discussed~~disclosure requirements in ~~Part I, “Item 1A. Risk Factors,” in our Annual Report on Form 10-K for the year ended~~ ~~December 31, 2013~~ (Form 10-K). You should carefully consider the risks described in our Form 10-K, which could materially affect our business, financial condition or future results. The risks described in our Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or results of operations. If anyRegulation S-K of the ~~risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.~~SEC and therefore not required to provide this information.

2731

PDI, Inc.

Item 5. Other Information

~~None.~~The Board of Directors adopted an amendment to the Company’s By-laws on November 6, 2013 to replace the “advance notice provisions” with which stockholders of the Company must comply in order to propose business to be brought at the annual meeting of stockholders, or to propose a nominee for election as director at the annual meeting of stockholders.

Under the replaced provisions, a stockholder was required to provide the Company with advance notice of an item of business or director nominee no earlier than 60 days nor later than 30 days before the annual meeting date. However, if the Company provided less than 40 days notice of the annual meeting date, then the stockholders’ notice must be given to the Company no later than 10 days after publication of the meeting date.

The amended provisions require advance notice to be given by the stockholder to the Company at least 90 and no more than 120 days before the anniversary of the Company’s previous annual meeting date. Further, stockholders giving such advance notice must disclose certain information concerning themselves such as material pending litigation, relationships between the stockholder and the Company and its affiliates, any material interest of the stockholder in, and any contract or agreement with the Company, its affiliates, or any of its principal competitors.

Any stockholder giving advance notice of a proposed item of business to be brought before the annual meeting must describe the item of business, the reasons for bringing such item before the meeting and any interest of the stockholder in such item of business. Also, the proponent must provide a description of any material arrangements or understandings of the proposing stockholder and any other person in connection with such item of business.

Any stockholder giving advance notice to propose a nominee for director at the annual meeting must also give disclosure of the information described above with respect to the stockholder. In addition, to be a valid nomination for director, the proposed candidate must deliver the Company’s written questionnaire for director nominees, a written representation and agreement on the Company’s form that the candidate is not and will not become party to any agreement, arrangement or understanding (i) as to how such nominee will act or vote on any issue or question before the directors, (ii) concerning voting that could limit the nominee’s ability to comply with the fiduciary duties of directors under applicable law, or (iii) with respect to direct or indirect compensation. Further, the candidate must deliver an agreement to comply with applicable Company policies and guidelines for directors with respect to matters such as corporate governance, conflict of interest, confidentiality and stock trading.

Item 6. Exhibits



Exhibit No.		Description

3(ii)		Amendment to By-Laws

10.1*		Collaboration Agreement dated as of August 19, 2013

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

101		The following financial information from this Quarterly Report on Form 10-Q/A for the fiscal quarter ended ~~March 31, 2014~~September 30, 2013 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Condensed Consolidated Financial Statements.

PDI, Inc.

* Portions of this agreement have been omitted from the filed Exhibit, and filed separately with the Commission together with a Request for Confidential Treatment.

2833

PDI, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Date:	~~August 19,~~September 29, 2014	PDI, Inc.
		(Registrant)

		/s/ Nancy S. Lurker
		Nancy S. Lurker
		Chief Executive Officer

		/s/ Jeffrey Smith
		Jeffrey Smith
		Chief Financial Officer

2934